Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A New Filter for Isolation of Circulating Tumor Cells by Only Blood Filtration.

Methods in molecular biology (Clifton, N.J.)·2026

Same author

Oncologic outcome and safety profile of first-line enfortumab vedotin plus pembrolizumab vs. conventional chemotherapy in advanced urothelial cancer.

Exploration of targeted anti-tumor therapy·2026

Same author

Anti-PD-1 plus anti-CTLA-4 blockade overcomes immune exclusion in NSCLC brain metastases by enhancing CD8<sup>+</sup> T cell responses and promoting tertiary lymphoid structure formation.

Nature communications·2026

Same author

The Lowest PSA Level Achieved Before CRPC Predicts Abiraterone Response But Not Enzalutamide Response in Metastatic CRPC.

The Prostate·2026

Same author

Impact of Pathological Lymphovascular Invasion of Lung Adenocarcinoma after Induction Chemoradiotherapy.

Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia·2026

Same author

Initial chemotherapy decreases transfusion dependence and enables definitive therapy in metastatic thymoma complicated by pure red cell aplasia: A case report.

Oncology letters·2026

Search research articles

Related Experiment Video

Updated: Jan 15, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Evaluating Local Doses for Prostate Cancer Treatment Using Low-Dose-Rate Brachytherapy Considering Oncological

Yasushi Nakai^1,2, Kenta Onishi¹, Isao Asakawa^2,3

¹Department of Urology, Nara Medical University, Nara, Japan.

|October 6, 2025

Summary

For prostate cancer patients treated with low-dose-rate brachytherapy (LDR-BT) alone, a biologically effective dose (BED) of 180-200 Gy2 optimizes outcomes. Combining LDR-BT with external beam radiation therapy (EBRT) suggests a BED of 200-220 Gy2 may be more appropriate for managing clinical failure and toxicity.

Keywords:

brachytherapy oncological control prostate cancer radiation dosage toxicity

More Related Videos

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Experiment Videos

Last Updated: Jan 15, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Area of Science:

Radiation Oncology
Medical Physics
Urologic Oncology

Background:

Evaluating treatment efficacy and toxicity in prostate cancer is crucial for optimizing patient outcomes.
Low-dose-rate brachytherapy (LDR-BT) and external beam radiation therapy (EBRT) are established treatment modalities.
Understanding the relationship between radiation dose and clinical outcomes is essential for personalized treatment planning.

Purpose of the Study:

To identify factors associated with clinical failure and toxicity in prostate cancer patients.
To determine optimal biologically effective dose (BED) thresholds for LDR-BT alone and combined with EBRT.
To establish BED cut-off values for predicting Grade 3 or higher toxicity.

Main Methods:

A cohort of 713 patients treated with LDR-BT alone and 534 patients treated with LDR-BT combined with EBRT were analyzed.
The Fine-Gray hazard model was used to assess factors related to clinical failure.
The Youden index was employed to determine BED cut-off values for toxicity.

Main Results:

For LDR-BT alone, BED thresholds of ≥180 Gy2 were associated with better clinical outcomes in low- and intermediate-risk patients.
A BED of 200 Gy2 was identified as a toxicity cut-off for LDR-BT alone.
For LDR-BT combined with EBRT, BED was not significantly associated with improved failure-free rates, but a BED cut-off of 220 Gy2 was determined for toxicity.

Conclusions:

A BED of 180-200 Gy2 appears optimal for prostate cancer treated with LDR-BT alone.
For combined LDR-BT and EBRT, a BED of 200-220 Gy2 may be more appropriate to balance efficacy and toxicity.
These findings support dose optimization in radiation therapy for prostate cancer.